Human Microbiome Applications in IVD and Other Healthcare

   Single User - $1,500
   Site License (one location, 10 users) - $2,250
   Corporate License - $3,000

Published Dec 6, 2017 | 280 Pages | Pub ID: KLI15545428

Human Microbiome Applications in IVD and Other Healthcare

The human body contains trillions of microbes. The term “microbiome” is used to refer to this community of microorganisms. Researchers increasingly consider the microbiome’s complicated relationship with its human host crucial to health.

Human Microbiome Applications in IVD and Other Healthcare
surveys the growing interest in the human microbiome in in vitro diagnostics (IVD) and other healthcare applications, touching on areas such as metagenomics, metabolomic profiling, and microbiome diagnostics, among others.

While study of the microbiome has attracted enthusiastic media attention and venture capital, its findings are largely preliminary. Still, some IVD companies have already launched tests to measure changes in the microbiome to monitor disease progress. Human Microbiome Applications in IVD and Other Healthcare notes selected molecular microbiome-based tests, microbiome-based diagnostic biomarkers, and precision or personalized medicine approaches to the microbiome.

Human Microbiome Applications in IVD and Other Healthcare notes pharmaceutical company interest in the microbiome as well. Spurred on by the Human Microbiome Project, pharmaceutical companies have become more interested in microbiome research. Many players in the microbiome market are amassing knowledge and data about the microbiome in order to partner with pharmaceutical firms interested in developing new therapeutics. Microbiome-based therapeutic approaches are discussed, including fecal microbiota transplants (FMT) and selected novel therapies. Select current microbiome-related drug candidates are noted in Human Microbiome Applications in IVD and Other Healthcare as well.

Microbiome companies and start-ups offer a wide array of products and services. They can be roughly grouped into therapeutics-based companies, research-based companies, and direct-to-consumer service providers. Despite the fact that efforts to develop microbiome-based diagnostics and therapies remain in their early stages, microbiome companies have attracted significant investment, which is discussed in the report.

Company Profiles

Human Microbiome Applications in IVD and Other Healthcare profiles players in the microbiome market, companies involved in testing, therapeutics, sample preparation and processing, and more, including:
  • 4D Pharma plc
  • Abbott Diagnostics
  • Abbvie
  • Aces Health
  • AdvancingBio
  • Agilent Technologies Inc.
  • Anaeropharma Science
  • AOBiome, LLC
  • Aperiomics, Inc.
  • Arivale
  • Atlas Biomed
  • AvidBiotics
  • Beckman Coulter / Danaher
  • Becton, Dickinson and Company (BD)
  • Biocartis Group
  • The BioCollective
  • BioGaia Pharma AB
  • Biohit OYJ
  • Biomecite Diagnostics
  • bioMérieux Inc.
  • Bio-Rad Laboratories, Inc.
  • Biose
  • Blis Technologies
  • Bruker Corporation
  • C3J Therapeutics (formerly C3 Jian)
  • Capsugel
  • Charles River Laboratories, Inc.
  • CIPAC Therapeutics
  • CLC bio (a QIAGEN company)
  • Clinical-Microbiomics
  • Copan Diagnostics, Inc.
  • CosmosID
  • Covaris
  • Crestovo (Finch Therapeutics Group)
  • Danaher Corporation
  • Dermala
  • DermTech
  • Diversigen
  • DNA Genotek
  • DNAnexus, Inc.
  • Eagle Genomics
  • Eligo Bioscience
  • ENTEROME Bioscience SA
  • EpiBiome
  • Eppendorf AG
  • Evelo Biosciences
  • Evolve Biosystems
  • Finch Therapeutics Group
  • GALT
  • GATC Biotech AG
  • Genetic Analysis AS
  • GENEWIZ, Inc.
  • GlaxoSmithKline plc
  • Human Longevity, Inc. (HLI)
  • Illumina
  • IS-Diagnostics
  • ISOThrive LLC
  • Janssen Biotech (Johnson & Johnson)
  • Kallyope
  • Labcyte
  • Luminex Corporation
  • Mayo Medical Laboratories
  • Menarini-Silicon Biosystems
  • Merck & Co., Inc.
  • Metabiomics Corporation
  • MetaboGen AB
  • Metabolon, Inc.
  • Microbiome
  • Microbiome Insights
  • MicroBiome Therapeutics (MBT)
  • Mitra Biotech
  • MyBiotics
  • Naked Biome
  • Nestlé Health Science
  • New England Biolabs
  • Nizo
  • Norgen Biotek
  • OncoImmunity
  • One Codex
  • OpenBiome
  • Optibiotix
  • OraSure Technologies, Inc.
  • Osel, Inc.
  • PerkinElmer, Inc. (Pe)
  • Pfizer, Inc.
  • Phase Genomics
  • Proderm IQ
  • Prodigest
  • Promega Corporation
  • PureFlora Inc.
  • Quay Pharma
  • Rebiotix
  • Resphera Biosciences
  • Ritter Pharmaceuticals, Inc.
  • Roche Diagnostics
  • Sabinsa Corporation
  • ScreenCell
  • Second Genome
  • Seres Therapeutics
  • Shimadzu Corporation
  • Siolta Therapeutics
  • Symbiotic Health
  • SynCo Bio Partners B.V.
  • Synlogic
  • Synthetic Biologics
  • Thermo Fisher Scientific, Inc.
  • TNO
  • Triskelion
  • uBiome
  • Vaiomer
  • Vedanta Biosciences
  • ViThera Pharmaceuticals
  • Waters Corporation
  • Whole Biome
  • Xycrobe Therapeutics, Inc.
  • Zymo Research
The information presented in this report is the result of data gathered from government reports, company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press.

Visit Kalorama Information's 'In Vitro Diagnostics' curated page for complete coverage of the IVD market.

In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.